A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
13 07 2021
Historique:
entrez: 14 7 2021
pubmed: 15 7 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Epitope III, a highly conserved amino acid motif of

Identifiants

pubmed: 34260404
pii: 2104242118
doi: 10.1073/pnas.2104242118
pmc: PMC8285954
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Epitopes 0
Peptides 0
Tetraspanin 28 0
Viral Envelope Proteins 0
glycoprotein E2, Hepatitis C virus 157184-61-7

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Elife. 2020 Mar 03;9:
pubmed: 32125272
Bioinformatics. 2009 Jun 1;25(11):1422-3
pubmed: 19304878
PLoS One. 2013 May 22;8(5):e63906
pubmed: 23717507
Gastroenterology. 2007 Feb;132(2):667-78
pubmed: 17258731
EMBO J. 2001 Jan 15;20(1-2):12-8
pubmed: 11226150
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W233-8
pubmed: 18442991
J Virol. 1999 Aug;73(8):6235-44
pubmed: 10400713
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15394-9
pubmed: 8986822
J Virol. 2015 Jan;89(1):492-501
pubmed: 25339761
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
J Virol. 2006 Sep;80(17):8695-704
pubmed: 16912317
PLoS One. 2013;8(4):e59004
pubmed: 23565140
Gastroenterology. 2009 Jun;136(7):2377-86
pubmed: 19303013
J Virol. 2015 Feb;89(4):2170-81
pubmed: 25473061
Vaccine. 2004 Feb 25;22(8):991-1000
pubmed: 15161076
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
PLoS One. 2014 Jan 06;9(1):e84346
pubmed: 24400084
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12768-12773
pubmed: 27791120
Nature. 2007 Dec 13;450(7172):964-72
pubmed: 18075575
Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):338-51
pubmed: 27147491
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30
pubmed: 17392433
PLoS Pathog. 2017 Dec 18;13(12):e1006735
pubmed: 29253863
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
Sci Adv. 2020 Jul 24;6(30):eabb5642
pubmed: 32754640
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
PLoS One. 2013;8(3):e59776
pubmed: 23527266
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Virol. 2004 Feb;78(3):1448-55
pubmed: 14722300
J Virol. 2006 Aug;80(16):7844-53
pubmed: 16873241
Protein Sci. 2018 Jan;27(1):135-145
pubmed: 28884485
PLoS One. 2011;6(8):e22477
pubmed: 21829626
Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3
pubmed: 30439340
Nature. 2014 May 15;509(7500):381-4
pubmed: 24553139
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8449-54
pubmed: 17494735
Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):432-8
pubmed: 14993666
Science. 2013 Nov 29;342(6162):1090-4
pubmed: 24288331
J Virol. 2007 Jan;81(2):588-98
pubmed: 17079281
Nat Rev Dis Primers. 2017 Mar 02;3:17006
pubmed: 28252637
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10149-54
pubmed: 15220475
J Virol. 2012 Dec;86(23):12686-94
pubmed: 22973024
Science. 1998 Oct 30;282(5390):938-41
pubmed: 9794763
Protein Sci. 2014 Jan;23(1):47-55
pubmed: 24265211
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7418-22
pubmed: 23589879
Cold Spring Harb Perspect Med. 2020 Jan 2;10(1):
pubmed: 31501263
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10690-5
pubmed: 25002515
Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):412-424
pubmed: 29773899
Vaccine. 2010 Aug 31;28(38):6367-73
pubmed: 20619382

Auteurs

Lu Deng (L)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Nancy Hernandez (N)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Lilin Zhong (L)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

David D Holcomb (DD)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Hailing Yan (H)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Maria Luisa Virata (ML)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Sreya Tarafdar (S)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Yanqun Xu (Y)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Yong He (Y)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Evi Struble (E)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002.

Harvey J Alter (HJ)

Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD 20892 halter@dtm.cc.nih.gov pei.zhang@fda.hhs.gov.

Pei Zhang (P)

Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993-0002; halter@dtm.cc.nih.gov pei.zhang@fda.hhs.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH